Oncology drug developers must start asking questions in preparation of FDA’s dose optimization initiative.
Julie Bullock
Advertisement
SVP, Clinical Pharmacology & Translational Medicine
Articles by Julie Bullock
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Senate Democrats Expand Efforts to Expose Details of MFN Pharma Deals
2
Novo Nordisk Responds to FDA’s Warning Letter Regarding 2025 PADE Inspection
3
FDA Grants Priority Review to Enhertu as Treatment for Patients with HER2-positive Early Breast Cancer
4
Pharmaceutical Executive Daily: FDA Expands Approval of Leucovorin
5